United States Patent 12,275,715 (Drug Patent): Scope, Claim Coverage, and Competitive Landscape
What does US 12,275,715 claim at a high level?
US 12,275,715 is a composition and therapeutic-use patent built around a broad generic chemical scaffold (Formula I) plus narrowed species (Formula Ia/Ib and enumerated compounds). The enforcement structure is standard for IDH1-mutant oncology: compound (and salts) + pharmaceutical composition + methods for mutant isocitrate dehydrogenase inhibition and 2-hydroxyglutarate reduction + treatment of cancers driven by mutant IDH1, with explicit tumor types and IDH1 R132 variants.
The independent claim is Claim 1, which defines:
- A compound of Formula I (or pharmaceutical salt)
- A wide set of substituent definitions for ring atoms and functional groups
- Functional provisos limiting allowed combinations when A = H (binding of R1 and R2 options and a ring-formation restriction)
The remaining claims layer in:
- Claim 2: pharmaceutical composition
- Claims 3-4: treatment methods for mutant-IDH-associated diseases including glioma/GBM/AML and solid tumors
- Claims 5-9: method claims narrowed to specific sub-formulas (Ia, Ia-1, Ia-2, Ib, Ib-1) tied to Claim 4
- Claims 10-11: enumerated species (specific chemical names) that also function as embodiments for the method claims
- Claims 13-16: disease-specific methods (AML) and mechanism-level methods (inhibit mutant IDH and reduce 2-HG)
- Claims 17-18: additional mechanism methods for enumerated species
- Claims 19-23: chondrosarcoma treatment with explicit IDH1 mutation types (R132H, 132C, R132G, R132S, R132L)
How is Formula I structured, and where is the real scope?
Core scaffold: Formula I with controlled atom sets
Claim 1 requires a compound of Formula I where key variable groups are constrained as follows:
- W1 and W2: each independently CH, CF, or N
- W3: independently CR2 or N
- U: N or CR6
- A: selected from a long list that includes hydrogen/deuterium and extensive carbonyl and heteroatom-bearing groups:
- H, D
- Halogen, CN
- -CHO, -COOH, -COOR
- -C(O)NH2, -C(O)NHR
- Sulfonyl variants such as R′S(O)2—, -SOMe, -SO2Me, R′S(O)—
- -O(CH2)nC(O)R′
- -OCH2… type substituent patterns (via later R2/R′ definitions)
- Heteroaryl and heteroaryl-like selections
- X and Y constraints: X and Y are independently C, N, NR′, S, or O, but:
- The ring containing X and Y can have no more than 4 N or NH atoms
- The ring can have no more than one S or O atom
- S and O are not contiguous
- R, R′ definitions are extremely broad (H to substituted aryl/heteroaryl), with optional substitution at each occurrence
Substituent universes: R1/R2/R3/R4/R5/R6 are the scope engine
Claim 1 expands coverage through multiple substituent fields:
-
R1: OH, CN, halogen, CHCF2, CF3, C1-C6 alkyl, C1-C6 alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, each optionally substituted
-
R2: H, OH, CN, halogen, CF3, CHF2, benzyl, alkyl/alkoxy, plus many functional substituents including:
- O(CH2)nR′
- O(CH2)nC(O)NHR′
- O(CH2)nC(O)R′
- amino and acylamino variants such as NHR7, N(R7)(R8), NHC(O)R7, NHS(O)R7, NHS(O)2R7, NHC(O)OR7, NHC(O)NHR7
- sulfonamide-like substitutions
- OCHR′R7 or CHRR′ / OCHR′R7 patterns
-
R3: H, C1-C6 alkyl, or -OH
-
R4 and R5: each independently H, halogen, CH2OH, C1-C3 alkyl, or C1-C3 alkyl optionally substituted with halogen; or together form a ring
-
R6: aryl/heteroaryl/cycloalkyl/alkoxy/alkyl variants, optionally halogen/oxo substituted
Rings and fusion: R and R′ can cyclize
Claim 1 includes explicit “combine-to-ring” options:
- R1 and R2 can combine to form a C4-C6 cycloalkyl or a 3- to 8-membered heterocycle containing N/O/S
- R4 and R5 can combine to form a C3-C6 cycloalkyl or a C3-C6 heterocycle
- R7 and R8 can combine to form a 3- to 8-membered heterocycle or heteroaryl ring
These “combining” features matter for freedom-to-operate because they expand the claim to ring-locked analogs beyond simple acyclic substitutions.
Defined stereochemistry and isotopic inclusion
Claim language explicitly includes:
- Deuterium through A = D (and later named species can still be hydrogenated variants)
- Enantiomers by inclusion of (1S)/(1R) in enumerated species (Claim 10 species list includes both)
Hard proviso that narrows when A = H
The claim includes a specific limitation:
- If A is H, then:
- R1 is not C1-C6 alkyl and not C1-C6 alkoxy
- R1 and R2 cannot combine to form a 3- to 8-membered heterocycle
This proviso is the single explicit “off switch” for a major branch of chemical space and is often the pivot point for design-around.
What does the patent cover in practice: composition and use claims
Pharmaceutical composition
- Claim 2: compound of Claim 1 + pharmaceutically acceptable carrier
This typically supports product claims for generic/similar formulations if the compound scope is met.
Cancer treatment methods (IDH mutant-associated diseases)
-
Claim 3-4: method of treating disease associated with mutant isocitrate dehydrogenase.
-
Disease list includes:
- Glioma
- Glioblastoma multiforme (GBM)
- Acute myeloid leukemia (AML)
- Chondrosarcoma
- Intrahepatic cholangiocarcinoma (IHCC)
- Myelodysplastic syndrome (MDS)
- Myeloproliferative disease (MPD)
- Solid tumor
-
Claim 4 is the broad method claim; Claims 5-9 restrict to sub-formulas Ia / Ia-1 / Ia-2 / Ib / Ib-1, but those are still within the same Formula-driven regime.
Species-anchored embodiments (Claim 10-11)
Claim 10 enumerates multiple named compounds that are all embodiments of Claim 1 species. Claim 11 further narrows to a small set from that list.
The practical enforceable “core” here is that:
- even if a competitor avoids the general Formula I by selecting a different substitution pattern,
- the patent still asserts protection through specific exemplified compounds with tight structural identity.
Mechanism of action language and biomarker linkage
The patent expressly claims functional mechanism coverage:
- Claim 15: method of inhibiting mutant isocitrate dehydrogenase
- Claim 16: method of reducing 2-hydroxyglutarate (2-HG)
- Claims 17-18: similar mechanism methods but restricted to particular enumerated compounds (Claim 10 species)
Biomarker coupling (2-HG) is a strong litigation lever because it creates a direct, measurable therapeutic effect tied to mutant IDH biology.
Species coverage: what exact compounds are explicitly included?
Claim 10 includes a long list of enumerated chemical species. Several are repeated across later claims as the “preferred” set, and they cluster around a recurring structural motif:
- 6-chloro substituted dihydroquinolinone / dihydropyridone scaffolds
- carbonitrile or carboxamide or carboxylate functionality
- a trifluoromethyl group in multiple examples
- multiple variants of ring substituents including:
- fluoro, methoxy
- azetidinyl
- cyclopropyl
- difluoroazetidinyl
- difluorocyclobutyl methoxy
- pyridin-2-ylmethoxy
- stereochemical variations (1S)/(1R)
Claim 19 then tightens further for a specific target compound used for chondrosarcoma, with derivatives including salt/hydrate/solvate/prodrug/isomer/tautomer coverage.
The explicit chondrosarcoma compound in Claim 19
- 5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
- plus:
- pharmaceutically acceptable salt
- an enantiomer
- hydrate/solvate
- prodrug
- isomer
- tautomer
This claim is structured to capture not only the exact identity but also common derivative forms.
What is the patent landscape risk profile?
Even without prosecution history or family data in the input, the claim structure indicates the patent is designed for stacking coverage across:
1) broad generic structural formula (Formula I),
2) method-of-use claims (IDH mutant cancers),
3) explicit mechanism/biomarker claims (mutant IDH inhibition, 2-HG reduction),
4) explicit tumor-type claims including chondrosarcoma with IDH1 R132 variant specificity,
5) enumerated chemical species for fallback position.
Coverage matrix (mapping claim types to enforcement posture)
| Claim segment |
What it protects |
Typical competitive risk |
| Claim 1 (Formula I) |
Large chemical universe via substituent “plug-ins” |
High: many close analogs may still fall inside unless they break a specific proviso or substituent constraint |
| Claims 2-4 |
Product formulation and broad treatment |
High: market entry could trigger both product and method exposure |
| Claims 15-18 |
Mechanism and 2-HG biomarker reduction |
High: supports clinical and marketing claims around IDH pathway effects |
| Claims 19-23 |
Chondrosarcoma with IDH1 R132 mutations |
Medium-to-high: design-around must address both chemical structure and the molecular genetics-to-therapeutic correlation used in enforcement |
Likely design-around pressure points (derived from the claim text)
The following are the most litigable “fault lines” in the claim language you provided:
1) A = H proviso
- R1 cannot be C1-C6 alkyl or C1-C6 alkoxy
- R1 and R2 cannot combine to form a 3- to 8-membered heterocycle
This creates a narrow but critical workaround zone: if a competitor chooses hydrogen at A, it must avoid those forbidden R1/R2 combinations.
2) S/O ring constraint
The ring containing X and Y cannot have:
- more than one S or one O
- more than 4 N or NH atoms
- S and O not contiguous
This limits many heteroaryl ring patterns.
3) Enumerated species as “backstop”
Even if Formula I is skirted, the enumerated compounds in Claim 10 remain covered. The practical strategy for competitors is often to avoid those exact embodiments.
4) Chondrosarcoma claim derivative capture
Claim 19 covers:
- salt, enantiomer, hydrate, solvate, prodrug, isomer, tautomer
That reduces standard derivative-based design-around options for the one explicit compound.
Key Takeaways
- US 12,275,715 is built around a broad Formula I covering diverse substituent patterns, reinforced by explicit enumerated compound species and multiple therapeutic/molecular-mechanism method claims.
- The claim set is structured for stacked enforcement: composition + treatment of mutant-IDH-associated cancers + mutant IDH inhibition and 2-HG reduction + chondrosarcoma with IDH1 R132 variant specification.
- The most actionable design-around constraints in Claim 1 are the A = H proviso (forbids certain R1 and R1/R2 cyclization outcomes) and the heteroaryl ring X/Y rules (limits N count and S/O content/adjacency).
- The enumerated species list and the chondrosarcoma compound derivative coverage in Claim 19 reduce the space for “minor” chemical form changes (salts, tautomers, enantiomers, prodrugs).
FAQs
1) Is Claim 1 purely chemical, or does it include functional restrictions?
It is primarily chemical (Formula I and substituent definitions), but it includes structural provisos (not functional assays) such as the restrictions when A = H, plus ring composition rules for X/Y.
2) What diseases are explicitly listed in the method claims?
The claim text lists glioma, GBM, AML, chondrosarcoma, IHCC, MDS, MPD, and solid tumors, all tied to mutant isocitrate dehydrogenase.
3) Does the patent assert a biomarker mechanism?
Yes. It includes methods for reducing 2-hydroxyglutarate (2-HG) and methods for inhibiting mutant isocitrate dehydrogenase.
4) Are stereoisomers covered?
Yes. Claim 10 includes compounds with (1S) and (1R) stereochemistry, and Claim 19 explicitly covers an enantiomer of the chondrosarcoma compound.
5) Does Claim 19 cover derivatives like prodrugs and hydrates?
Yes. Claim 19 covers salt, enantiomer, hydrate, solvate, prodrug, isomer, and tautomer for the listed chondrosarcoma compound.
References
[1] United States Patent 12,275,715, claims 1-23 (claim text provided in prompt).
